Pune: DeepTek announces that its revolutionary chest X-ray screening solution, Genki, has received approval from the Thai Food and Drug Administration (FDA). Genki leverages cutting-edge AI technology to classify scans as normal and abnormal along with further analysing over 19 different chest pathologies. By automating the interpretation of chest X-rays it offers immense potential for improving medical diagnosis and treatment efficiency for lung diseases such as tuberculosis, pneumonia, lung cancer, and chronic pulmonary diseases, all of which pose significant health challenges globally.
The solution’s effectiveness is backed by independent evaluations conducted by organisations like Stop TB Partnership, Friends for International TB, and several others across the globe.
The organisation is actively collaborating with leading hospitals and medical institutions across Thailand to integrate its AI solutions into their existing radiology workflows. The seamless integration of its technology ensures that healthcare providers can benefit from the power of AI without disrupting their established processes, paving the way for widespread adoption and market expansion.
Commenting on the Thai FDA approval, Ajit Patil, Co-Founder, DeepTek, said “Thailand has gained a reputation for offering excellent medical resources and healthcare services by thinking ahead of time. The recent approval from the Thai regulatory body testifies to the readiness of the country to adopt AI into their healthcare services. We are happy to have partnered with leading healthcare providers in Thailand and be backed by Shimadzu Asia Pacific. We look forward to tapping vast opportunities in Thailand and beyond.”
